Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Maria Louise Kobberø"'
Autor:
Mariane H. Schleimann, Maria-Louise Kobberø, Line K. Vibholm, Kathrine Kjær, Leila B. Giron, Kathleen Busman-Sahay, Chi Ngai Chan, Michael Nekorchuk, Manuel Schmidt, Burghardt Wittig, Tine E. Damsgaard, Peter Ahlburg, Michel B. Hellfritzsch, Kaja Zuwala, Frederik H. Rothemejer, Rikke Olesen, Phillipp Schommers, Florian Klein, Harsh Dweep, Andrew Kossenkov, Jens R. Nyengaard, Jacob D. Estes, Mohamed Abdel-Mohsen, Lars Østergaard, Martin Tolstrup, Ole S. Søgaard, Paul W. Denton
Publikováno v:
EBioMedicine, Vol 45, Iss , Pp 328-340 (2019)
Background: TLR9 agonists are being developed as immunotherapy against malignancies and infections. TLR9 is primarily expressed in B cells and plasmacytoid dendritic cells (pDCs). TLR9 signalling may be critically important for B cell activity in lym
Externí odkaz:
https://doaj.org/article/6617a90ba47a4cea9fc13ade7be6bc01
Autor:
Mohamed Abdel-Mohsen, Jacob D. Estes, Martin Tolstrup, Manuel Schmidt, Kathleen Busman-Sahay, Line K. Vibholm, Andrew V. Kossenkov, Kathrine Kjær, Rikke Olesen, Michel Bach Hellfritzsch, Paul W. Denton, Michael Nekorchuk, Leila B. Giron, Lars Østergaard, Maria Louise Kobberø, Chi Ngai Chan, Tine Engberg Damsgaard, Peter Ahlburg, Mariane H. Schleimann, Jens R. Nyengaard, Phillipp Schommers, Florian Klein, Burghardt Wittig, Kaja Zuwala, Frederik H. Rothemejer, Harsh Dweep, Ole Schmeltz Søgaard
Publikováno v:
Schleimann, M H, Kobberø, M-L, Vibholm, L K, Kjær, K, Giron, L B, Busman-Sahay, K, Chan, C N, Nekorchuk, M, Schmidt, M, Wittig, B, Damsgaard, T E, Ahlburg, P, Hellfritzsch, M B, Zuwala, K, Rothemejer, F H, Olesen, R, Schommers, P, Klein, F, Dweep, H, Kossenkov, A, Nyengaard, J R, Estes, J D, Abdel-Mohsen, M, Østergaard, L, Tolstrup, M, Søgaard, O S & Denton, P W 2019, ' TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes ', EBioMedicine, vol. 45, pp. 328-340 . https://doi.org/10.1016/j.ebiom.2019.07.005
EBioMedicine
EBioMedicine
Background TLR9 agonists are being developed as immunotherapy against malignancies and infections. TLR9 is primarily expressed in B cells and plasmacytoid dendritic cells (pDCs). TLR9 signalling may be critically important for B cell activity in lymp